Cover Image
市場調查報告書

子宮頸癌診斷市場分析:檢驗類別(子宮頸抹片檢查或細胞學檢驗,HPV檢驗,子宮頸活檢,細胞檢驗),及市場區隔預測

Cervical Cancer Diagnostic Market Analysis By Test Type (Pap Testing Or Cytology Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy) And Segment Forecasts To 2024

出版商 Grand View Research, Inc. 商品編碼 374590
出版日期 內容資訊 英文 79 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
子宮頸癌診斷市場分析:檢驗類別(子宮頸抹片檢查或細胞學檢驗,HPV檢驗,子宮頸活檢,細胞檢驗),及市場區隔預測 Cervical Cancer Diagnostic Market Analysis By Test Type (Pap Testing Or Cytology Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy) And Segment Forecasts To 2024
出版日期: 2016年09月27日 內容資訊: 英文 79 Pages
簡介

本報告提供全球子宮頸癌診斷市場相關調查,市場概要和今後預測,彙整各市場區隔及地區別趨勢,及加入此市場的主要企業簡介等資料。

第1章 摘要整理

第2章 市場概要

第3章 市場變動,趨勢,範圍

  • 市場區隔和範圍
    • 推動市場的要素分析
    • 阻礙市場的要素分析
  • 滲透與成長預測製圖
  • SWOT分析
  • 產業分析:波特五力分析

第4章 市場類別1:檢驗類別預測與趨勢分析

  • 子宮頸癌診斷市場
  • 子宮頸抹片檢查
  • HPV檢驗
  • 子宮頸活檢
  • 細胞檢驗

第5章 市場類別2:各地區預測與趨勢分析

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第6章 競爭環境

  • 策略架構
  • 市場進入分類
  • 企業簡介
目錄
Product Code: GVR-1-68038-127-6

The global cervical cancer diagnostic market was valued at USD 7 billion in 2015 and is expected to reach a value of USD 12 billion by 2024, according to a new report by Grand View Research, Inc. The key driving factors include the rising prevalence of cervical cancer, evolving screening technology, and various programs that promote routine check up and screening. According to the data published by the WHO, in 2012, over 270,000 women died due to cervical cancer, majority of which were from the developing countries. It is one of the most common cancer type diagnosed in women. Some of the etiological factors are multiple sex partners, and changing lifestyle, such as drinking & smoking and increased stress levels.

Furthermore, favorable government initiatives and increasing number of awareness programs are further expected to promote the market growth in coming few years. The National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, are working towards promoting the necessity for early screening of cervical cancer amongst mid aged women.

There is an increasing demand for technologically advanced diagnostic procedures that facilitate the early intervention of the disease. The industry players are focused on developing innovative technological solutions for accurate and efficient results. Advancement in screening techniques, such as use of biomarkers, is gaining importance. The upsurge in technological developments is anticipated to further drive industry growth.

On account of increasing adoption of Pap test, the number of deaths due to cervical cancer has declined significantly in past few years. It helps detect precancerous lesions at an early state and, thus, reduces the number of cervical cancer cases. The American Cancer Society stated that the cervical cancer cases in last 40 years in the U.S. have declined by more than 50%. Initially, the Pap test screening was carried out every year which lead to further unnecessary procedures. However, the American Cancer Society now recommends that women in the age group of 21 to 29 should undergo Pap test every 3 years.

Further key findings from the report suggest:

In 2015, the Pap testing segment held majority of the market share of 49.6%. The segment's large share can be attributed to the high efficiency of the tests in early diagnosis. Also, the increasing awareness about the impact of early diagnosis contributed to its growth.

In 2015, North America was the leading regional market with a revenue share of 48.3%. The U.S. is a key market in North America. Growing incidence of cervical cancer coupled with initiatives undertaken by government agencies in the form of awareness programs pertaining to the early screening of the disease are key factors for the country's large market share.

Asia Pacific is expected to witness lucrative growth over the forecast period growing at a CAGR of 9.6%. The various steps undertaken by governments of developing countries such as India, China, Philippines, and other in order to improve healthcare infrastructure and to improve access to healthcare facilities are amongst key factors attributing to region's high growth. Also, high prevalence of cancer in developing nations and increasing consumer awareness levels drive the growth

This market is presently dominated by a few key participants such as Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Abbott Laboratories, OncoHealth Corp, Hologic, Inc., QIAGEN, Quest Diagnostics, Inc and Guided Therapeutics, Inc. The key players focus specially on developing innovative solutions for diagnosis. For instance, F. Hoffmann-La Roche Ltd., in 2014, launched automated CINtec PLUS cytology test that efficiently detects the presence of precancerous cells.

Table of Contents

Chapter 1: Executive Summary

Chapter 2: Market Snapshot

Chapter 3: Market Variables, Trends & Scope

  • 3.1. Market Segmentation & Scope
    • 3.1.1. Market driver analysis
      • 3.1.1.1. Growing incidence of cervical cancer in middle aged women
      • 3.1.1.2. Increasing number of awareness programs for cervical cancer screening
      • 3.1.1.3. Technological advancement
    • 3.1.2. Market restraint analysis
      • 3.1.2.1. Changes in regulatory guidelines for cervical cancer screening
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Cervical cancer diagnostic market-SWOT Analysis, by Factor(Political & Legal, Economic, and Technological)
  • 3.4. Industry Analysis-Porter's

Chapter 4: Market Categorization 1: Test Type Estimates & Trend Analysis

  • 4.1. Cervical cancer diagnostic market: Test Type Movement Analysis
  • 4.2. Pap Testing
    • 4.2.1. Pap testing market estimates and forecasts, 2013-2024(USD Billion)
  • 4.3. HPV Testing
    • 4.3.1. HPV testing estimates and forecasts, 2013-2024(USD Billion)
  • 4.4. Cervical Biopsies
    • 4.4.1. Cervical biopsies market estimates and forecasts, 2013-2024(USD Billion)
  • 4.5. Cystoscopy
    • 4.5.1. Cystoscopy market estimates and forecasts, 2013-2024(USD Billion)

Chapter 5: Market Categorization 2: Regional Estimates & Trend Analysis

  • 5.1. Cervical cancer diagnostic market Share by Region, 2013 & 2024
  • 5.2. North America
    • 5.2.1. North America cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024(USD Billion)
    • 5.2.3. U.S.
      • 5.2.3.1. U.S. cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024(USD Billion)
    • 5.2.4. Canada
      • 5.2.4.1. Canada cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024(USD Billion)
  • 5.3. Europe
    • 5.3.1. Europe cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024(USD Billion)
    • 5.3.2. Germany
      • 5.3.2.1. Germany cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024(USD Billion)
    • 5.3.3. UK
      • 5.3.3.1. UK cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024(USD Billion)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024(USD Billion)
    • 5.4.2. Japan
      • 5.4.2.1. Japan cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024(USD Billion)
    • 5.4.3. China
      • 5.4.3.1. China cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024(USD Billion)
  • 5.5. Latin America
    • 5.5.1. Latin America cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024(USD Billion)
    • 5.5.2. Brazil
      • 5.5.2.1. Brazil cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024(USD Billion)
    • 5.5.3. Mexico
      • 5.5.3.1. Mexico cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024(USD Billion)
  • 5.6. MEA
    • 5.6.1. MEA cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024(USD Billion)
    • 5.6.2. South Africa
      • 5.6.2.1. South Africa cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024(USD Billion)

Chapter 6: Competitive Landscape

  • 6.1. Strategy Framework
  • 6.2. Market Participation Categorization
  • 6.3. Company Profiles
    • 6.3.1. Abbott Molecular
      • 6.3.1.1. Company overview
      • 6.3.1.2. Financial performance
      • 6.3.1.3. Product benchmarking
      • 6.3.1.4. Strategic initiatives
    • 6.3.2. F. Hoffmann-La Roche Ltd
      • 6.3.2.1. Company overview
      • 6.3.2.2. Financial performance
      • 6.3.2.3. Product benchmarking
      • 6.3.2.4. Strategic initiatives
    • 6.3.3. QIAGEN
      • 6.3.3.1. Company overview
      • 6.3.3.2. Financial performance
      • 6.3.3.3. Product benchmarking
      • 6.3.3.4. Strategic initiatives
    • 6.3.4. Quest Diagnostics, Inc.
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Hologic, Inc.
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. Arbor Vita Corporation
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. OncoHealth Corporation
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. Dell Guided Therapeutics, Inc.
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives
    • 6.3.9. CooperSurgical, Inc.
      • 6.3.9.1. Company overview
      • 6.3.9.2. Financial performance
      • 6.3.9.3. Product benchmarking
      • 6.3.9.4. Strategic initiatives
    • 6.3.10. Becton, Dickinson and Company(BD)
      • 6.3.10.1. Company overview
      • 6.3.10.2. Financial performance
      • 6.3.10.3. Product benchmarking
      • 6.3.10.4. Strategic initiatives

List of Tables

  • TABLE 1: Global cervical cancer diagnostic market revenue, by test type, 2013 - 2024 (USD Billion)
  • TABLE 2: Global cervical cancer diagnostic market revenue, by region, 2013 - 2024 (USD Billion)
  • TABLE 3: North America cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
  • TABLE 4: U.S. cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
  • TABLE 5: Canada cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
  • TABLE 6: Europe cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
  • TABLE 7: Germany cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
  • TABLE 8: UK cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
  • TABLE 9: Asia Pacific cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
  • TABLE 10: Japan cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
  • TABLE 11: China cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
  • TABLE 12: Latin America cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
  • TABLE 13: Brazil cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
  • TABLE 14: Mexico cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
  • TABLE 15: MEA cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
  • TABLE 16: South Africa cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)

List of Figures

  • FIG. 1: Market summary
  • FIG. 2: Market trends & outlook
  • FIG. 3: Market segmentation & scope
  • FIG. 4: Market driver relevance analysis (Current & future impact)
  • FIG. 5: Market restraint relevance analysis (Current & future impact)
  • FIG. 6: Penetration & growth prospect mapping
  • FIG. 7: SWOT Analysis, by factor (Political & legal, economic and technological)
  • FIG. 8: Porter's Five Forces Analysis
  • FIG. 9: Cervical cancer diagnostic market: Test type outlook key takeaways
  • FIG. 10: Cervical cancer diagnostic market: Test type movement analysis
  • FIG. 11: Global Pap testing market estimates and forecasts, 2013 - 2024 (USD Billion)
  • FIG. 12: Global HPV testing market estimates and forecasts, 2013 - 2024 (USD Billion)
  • FIG. 13: Global colposcopy market estimates and forecasts, 2013 - 2024 (USD Billion)
  • FIG. 14: Global cervical biopsies market estimates and forecasts, 2013 - 2024 (USD Billion)
  • FIG. 15: Global cystoscopy market estimates and forecasts, 2013 - 2024 (USD Billion)
  • FIG. 16: Regional market place: Key takeaways
  • FIG. 17: Regional outlook, 2015 & 2024
  • FIG. 18: North America cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024(USD Billion)
  • FIG. 19: U.S. cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024(USD Billion)
  • FIG. 20: Canada cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
  • FIG. 21: Europe cervical cancer diagnostic market estimates and forecasts,by test type, 2013 - 2024 (USD Billion)
  • FIG. 21: Germany cervical cancer diagnostic market estimates and forecasts,by test type, 2013 - 2024 (USD Billion)
  • FIG. 22: UK cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
  • FIG. 23: Asia Pacific cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
  • FIG. 24: Japan cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
  • FIG. 25: China cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
  • FIG. 26: Latin America cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
  • FIG. 27: Brazil cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
  • FIG. 28: Mexico cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
  • FIG. 29: MEA cervical cancer diagnostic market estimates and forecasts, by test type 2013 -2024 (USD Billion)
  • FIG. 30: South Africa cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
  • FIG. 31: Strategy framework
Back to Top